Kayla Britt 8/21/26 Kayla Britt 8/21/26

When a Check Doesn’t Run

Kayla Britt 8/9/26 Kayla Britt 8/9/26

The Last Deterministic Thing: The Unified Capture Layer

Kayla Britt 7/30/26 Kayla Britt 7/30/26

Beyond the Weights: Harness Monitoring as the Validation Leash

Kayla Britt 7/18/26 Kayla Britt 7/18/26

Balancing the Equation: Why HITL Is a Variable, Not a Constant

Kayla Britt 7/2/26 Kayla Britt 7/2/26

AI as Autonomous Vehicles: Can We Detect When They Fail?

Kayla Britt 6/29/26 Kayla Britt 6/29/26

Why AI Validation Architecture Belongs in the FDA's Clinical Trial Pilot — And What We Told Them

Kayla Britt 6/12/26 Kayla Britt 6/12/26

Context is King: Why AI Validation is Driven by Validity Context

Kayla Britt 5/25/26 Kayla Britt 5/25/26

Bounding the Uncertainty: An Error Taxonomy for Non-Deterministic AI in Regulated Life Sciences

Kayla Britt 5/6/26 Kayla Britt 5/6/26

When Your AI Vendor Passes SOC 2 — and Still Fails GxP

Kayla Britt 4/23/26 Kayla Britt 4/23/26

The Safety Paradox: Why Frozen Models Aren’t Always Safer Than Agentic Ones

Kayla Britt 4/3/26 Kayla Britt 4/3/26

The $100M Question Your AI Can't Answer (Yet): Why Validation Is the Missing Variable in Pharma's AI ROI

Kayla Britt 3/25/26 Kayla Britt 3/25/26

Your Frozen Architecture May Have a Backdoor

Kayla Britt 3/14/26 Kayla Britt 3/14/26

Why AI Governance Fails Without a Control Layer: A House-of-AI-Trust Model for Regulated Drug Development

Kayla Britt 2/23/26 Kayla Britt 2/23/26

The Guidance Says What. The Next 12 Articles Show How

Kayla Britt 2/11/26 Kayla Britt 2/11/26

AI Trust is not a feeling - It’s a Validation Strategy

Kayla Britt 2/4/26 Kayla Britt 2/4/26

The Engineering of Uncertainty: Transparency in the Probabilistic Era

Kayla Britt 1/22/26 Kayla Britt 1/22/26

Human-in-the-Loop, Liability Still in Play

Kayla Britt 1/14/26 Kayla Britt 1/14/26

FDA & EMA Just Released AI Guiding Principles for Drug Development: Here’s What They Actually Mean

When a Check Doesn’t Run

The Last Deterministic Thing: The Unified Capture Layer

Beyond the Weights: Harness Monitoring as the Validation Leash

Balancing the Equation: Why HITL Is a Variable, Not a Constant

AI as Autonomous Vehicles: Can We Detect When They Fail?

Why AI Validation Architecture Belongs in the FDA's Clinical Trial Pilot — And What We Told Them

Context is King: Why AI Validation is Driven by Validity Context

Bounding the Uncertainty: An Error Taxonomy for Non-Deterministic AI in Regulated Life Sciences

When Your AI Vendor Passes SOC 2 — and Still Fails GxP

The Safety Paradox: Why Frozen Models Aren’t Always Safer Than Agentic Ones

The $100M Question Your AI Can't Answer (Yet): Why Validation Is the Missing Variable in Pharma's AI ROI

Your Frozen Architecture May Have a Backdoor

Why AI Governance Fails Without a Control Layer: A House-of-AI-Trust Model for Regulated Drug Development

The Guidance Says What. The Next 12 Articles Show How

AI Trust is not a feeling - It’s a Validation Strategy

The Engineering of Uncertainty: Transparency in the Probabilistic Era

Human-in-the-Loop, Liability Still in Play

FDA & EMA Just Released AI Guiding Principles for Drug Development: Here’s What They Actually Mean

History Rhymes: Why AI is the "Paper-to-Digital" Shift of Our Generation

The Capability Paradox: Why Soaring LLM Benchmarks Demand Stricter Validation